Two Shot Same Day Exception Rules for COVID-19
The This page specifies the COVID-19 logic implemented by ICE for recommendations before September 12, 2023.
For COVID-19 logic for recommendations as of September 12, 2023 onwards, see COVID-19 Vaccine Group - September 2023 Onwards.
Two Shot Same Day Exception Rules for COVID-19
For COVID-19 shots administered:
- before 10/25/2021, the Duplicate Shot, Same Day rules do
...
- NOT apply because absolute minimum intervals between dose 1 and dose 2 = 0 days (before 10/25/2021) in both the Pfizer COVID-19 2-dose
...
- series and Moderna COVID-19 2-dose
...
- series.
- on or after 10/25/2021, the Duplicate Shot, Same Day rules apply because absolute minimum intervals between dose 1 and dose 2 > 0 days (on or after 10/25/2021) in both the Pfizer COVID-19 2-dose series and Moderna COVID-19 2-dose series.
Panel | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||
|
COVID-19 Vaccine Group Evaluation and Forecasting Rules
General Rules for COVID-19
General rules are not series-specific; general rules apply to the entire vaccine group.
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Notes
|
Immunization Series and Selection Rules
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Name
Series Selection RulesThere are four series for this vaccine group: the Pfizer COVID-19 Child (5-17) 2-dose Series, Pfizer COVID-19 2-dose series, Moderna COVID-19 2-dose series, and Janssen COVID-19 1-dose series. The rules for determining which series applies are:
|
Immunization Series: Pfizer COVID-19 Child (5-17) 2-dose Series
The Pfizer COVID-19 Child (5-17) 2-dose Series is complete after 2 doses.
Vaccine Dose Parameters - Minimum and Routine Ages
...
Dose
...
Series Name
...
Absolute Minimum
Age
...
Routine
Age
...
Latest Recommended Age (less than)
...
1
Pfizer COVID-19 Child (5-17) 2-dose Series
...
0 days
5 years
...
5 years
...
218, 208, 213
...
N/A
...
2
...
Pfizer COVID-19 Child (5-17) 2-dose Series
...
0 days
5 years
5 years
...
N/A
Vaccine Dose Parameters - Minimum and Recommended Intervals
...
Doses
...
Series Name
...
Absolute Minimum Interval
...
Recommended Interval
...
Dose 1 to 2
...
Pfizer COVID-19 Child (5-17) 2-dose Series
...
17 days
...
21 days
...
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Special Rules
Rule for CVX 212 (Janssen COVID-19 Vaccine)
|
Immunization Series: Pfizer COVID-19 2-dose Series
The Pfizer COVID-19 2-dose series is complete after 2 doses.
Vaccine Dose Parameters - Minimum and Routine Ages
...
Dose
...
Series Name
...
Absolute Minimum
Age
...
Routine
Age
...
1
...
Pfizer COVID-19 2-dose Series
...
18 years
...
2
...
Pfizer COVID-19 2-dose Series
...
18 years
...
18 years
...
Vaccine Dose Parameters - Minimum and Recommended Intervals
...
Doses
...
Series Name
...
Absolute Minimum Interval
...
Minimum Recommended Interval
...
Dose 1 to 2
...
Pfizer COVID-19 2-dose Series
...
0 days
...
21 days
...
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Special Rules
Rule for CVX 218 (Pfizer COVID-19 Vaccine (5-11))
Rule for CVX 212 (Janssen COVID-19 Vaccine)
|
Immunization Series: Moderna COVID-19 2-dose series
The Moderna COVID-19 2-dose series is complete after 2 doses.
Vaccine Dose Parameters - Minimum and Routine Ages
...
Dose
...
Series Name
...
Absolute Minimum
Age
...
Routine
Age
...
Latest Recommended Age (less than)
...
1
...
Moderna COVID-19 2-dose Series
...
0 days
...
18 years
...
N/A
...
2
...
Moderna COVID-19 2-dose Series
...
N/A
Vaccine Dose Parameters - Minimum and Recommended Intervals
...
Doses
...
Series Name
...
Absolute Minimum Interval
...
Recommended Interval
...
Dose 1 to 2
...
Moderna COVID-19 2-dose Series
...
0 days
...
28 days
...
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Special Rules
Rule for CVX 218 (Pfizer COVID-19 Vaccine (5-11))
Rule for CVX 207 (Moderna COVID-19 Vaccine) Administered < 18 years old
Rule for CVX 212 (Janssen COVID-19 Vaccine)
|
Immunization Series: Janssen COVID-19 1-dose Series
...
Panel | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||||
Anchor |
|
Anchor | ||||
---|---|---|---|---|
|
- Once a patient completes:
- the Pfizer COVID-19 Series,
- and is < 5 years old
- and is > = 5 years old and < 12 years old (or will be < 12 years old at the recommended due date), recommend CVX 218 for the next target dose.
- and is > = 12 years old (or will be >= 12 years old at the recommended due date) and < 18 years old, recommend CVX 208 for the next target dose.
- and is > = 18 years old and is in the following series:
- Pfizer COVID-19 2-dose Series, recommend CVX 208 for the next target dose.
- Moderna COVID-19 2-dose Series, recommend CVX 207 for the next target dose.
- Janssen COVID-19 1-dose Series, recommend CVX 212 for the next target dose.
- the Pfizer COVID-19 Series,
Series Completion Special Rule
- Once a patient completes:
- the Pfizer COVID-19 (5-17) 2-dose series,
- and is < 18 years old, the recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
- and receives an additional dose1, the Recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
- the Pfizer COVID-19 2-dose series with CVX 208 as Dose 1 and Dose 2,
- and is >= 65 :
- if the execution date is < 3/17/2023, the recommendation is Not Recommended and the reason code is COMPLETE.
- if the execution date is >= 3/17/2023 and a bivalent vaccine (CVX 229, CVX 230, CVX 300, CVX 301, CVX 302, CVX 519, or CVX 520) has not been administered, recommend a dose of COVID-19 at the vaccine group level and recommended interval (8 weeks) or on 3/17/2023, whichever date is latest, along with recommendation reasons ADMINISTER_COVID19_BIVALENT_VACCINE and SUPPLEMENTAL_TEXT and Descriptive Text: "Patients who previously completed a 3-dose monovalent primary series are recommended to receive 1 bivalent booster dose, at least 8 weeks after completion of the monovalent primary series.
- and is >= 5 years old:
- if the execution date is >= 4/19/2023:
- See Section "Rules for Booster Dose", Bullet Point: "After completion of the Pfizer COVID-19 Series, the execution date is >= 3/17/2023, and the patient is < 5 years of age"
- if the execution date is >= 4/19/2023:
- if the execution date is < 9/2/2022:
- and is >= 5 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (5 months) or at recommended age (5 years), whichever date is later, along with recommendation reason code BOOSTER_DOSE.
if the execution date is >= 9/2/2022 and is < 4/19/2023:
and is >= 5 years old, recommend a booster dose of
COVID-19 (at vaccine group level) at
recommended interval (
8 weeks) or at recommended age (5 years), whichever date is later, along with recommendation reason
code BOOSTER_DOSE.
- and is >= 18 years and < 65 years old, the recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
- and receives an additional dose1 or booster dose2, the Recommendation is Not Recommended and the reason code is COMPLETE.
- and is >= 65 :
- the Pfizer COVID-19 2-dose series where not all doses administered were CVX 208 or the Moderna COVID-19 2-dose series,
- the Recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
- and receives an additional dose1, the Recommendation is Not Recommended and the reason code is COMPLETE.
- either the 1) Janssen COVID-19 1-dose series, 2) COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a 3) COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine, the Recommendation is Not Recommended/ COMPLETE_HIGH_RISK.
- the Pfizer COVID-19 (5-17) 2-dose series,
Rules for an Additional Dose1
- If a patient completes a COVID-19 vaccine series via the Pfizer 2-dose series or Moderna 2-dose series and receives an additional shot of CVX 208, CVX 207, or CVX 213:
- at < 28 days - 4 days after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum age and/or minimum interval."
- at >= 28 days - 4 days after series completion, then evaluate the shot as Valid.
- If a patient is >=12 years old, completes a COVID-19 vaccine series via the Pfizer COVID-19 (5-17) 2-dose series and receives an additional shot of CVX 218, CVX 208, 207, or CVX 213:
- at < 28 days - 4 days after series completion, then evaluate the shot as Invalid/ BELOW_MINIMUM_INTERVAL.
- at >= 28 days - 4 days, then evaluate the shot as Valid.
Rules for Booster Dose2
- If a patient completes a COVID-19 vaccine series via the Pfizer 2-dose series (with CVX 208 only) and a booster dose2 of CVX 208,
- at < 28 days - 4 days after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum age and/or minimum interval."
- at >= 28 days - 4 days after series completion, then evaluate the shot as Valid.
- If a patient completes a COVID-19 vaccine series via the Janssen 1-dose series and a booster dose of CVX 212, CVX 208, CVX 207, or CVX 213, then evaluate the booster dose as Valid.
Rules for Extra Shots After Additional Dose1and/or Booster Dose2
- For patients that completed the Pfizer COVID-19 Child (5-17) 2-dose Series,
- is < 12 years old, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
- is > = 12 years old and received an Additional Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Notes
|
COVID-19 Vaccines
...
CVX Code
...
Name
...
Moderna COVID-19 Vaccine
...
208
...
Pfizer COVID-19 Vaccine
...
500
...
COVID-19 Non-US Vaccine, Product Unknown
...
501
...
COVID-19 IV Non-US Vaccine (QAZCOVID-IN)
...
502
...
COVID-19 IV Non-US Vaccine (COVAXIN)
...
503
...
COVID-19 LAV Non-US Vaccine (COVIVAC)
...
504
...
COVID-19 VVnr Non-US Vaccine (Sputnik Light)
...
505
...
COVID-19 VVnr Non-US Vaccine (Sputnik V)
...
506
...
COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology)
...
507
...
COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbology Chinese academy of Sciences)
...
508
...
COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention)
...
509
...
COVID-19 PS Non-US Vaccine (EpiVacCorona)
...
510
...
COVID-19 IV Non-US Vaccine (BIBP, Sinopharm)
...
511
...
COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)
...
Combination Vaccines that Include COVID-19
No combination vaccines exist, at this time, that include COVID-19 and count toward completion of the Pfizer COVID-19 2-dose series.
...
borderColor | #CCFFFF |
---|---|
bgColor | #CCFFFF |
titleBGColor | #99FFFF |
borderStyle | solid |
CVX Code Specific Rules
CVX Code Absolute Minimum Age
If one of the CVX codes in the table above is administered below the absolute minimum age for that CVX code, then the Evaluation is Invalid and the reason code is BELOW_MINIMUM_AGE_VACCINE
CVX Code Absolute Maximum Age
If one of the CVX codes in the table above is administered above the absolute maximum age for that CVX code, then the Evaluation is Invalid and the reason code is ABOVE_MAXIMUM_AGE_VACCINE.
Rule for CVX 213
- If the patient receives CVX 213 for:
- Target Dose 1, evaluate the shot as Valid.
- Recommend Target Dose 2 at Vaccine Group level
- Recommended interval = 28 days
- Target Dose 2, evaluate the shot as Valid.
- If the patient receives CVX 213 for Target Dose 1 and CVX 212 (Janssen COVID-19 Vaccine) is reported for Target Dose 2, the Janssen COVID-19 1-dose Series applies and the series is complete. Therefore,
- evaluate Target Dose 2 (CVX 212) as Valid.
- evaluate Target Dose 1 as Accepted and the reason code is VACCINE_NOT_COUNTED_BASED_ON_MOST_RECENT_VACCINE_GIVEN.
- If the patient has CVX 213 on their patient record AND receives all recommended doses of a 1) COVID-19 vaccine not authorized by the FDA, but authorized by the WHO or 2) COVID-19 vaccine not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine, then
- evaluate CVX 213 shots given before series completion as Accepted/ VACCINE_NOT_COUNTED_BASED_ON_MOST_RECENT_VACCINE_GIVEN.
- Example Scenario #1 - Patient receives the following shots (listed in order): CVX 213, CVX 210 (AstraZeneca), CVX 210 (AstraZeneca)
- CVX 213 shot is evaluated as Accepted/ VACCINE_NOT_COUNTED_BASED_ON_MOST_RECENT_VACCINE_GIVEN
- Both CVX 210 shots are evaluated as Valid (series is complete via AstraZeneca 2-dose series)
- Example Scenario #2 - Patient receives the following shots (listed in order): CVX 210 (AstraZeneca), CVX 213, CVX 210 (AstraZeneca)
- CVX 213 shot is evaluated as Accepted/ VACCINE_NOT_COUNTED_BASED_ON_MOST_RECENT_VACCINE_GIVEN
- Both CVX 210 shots are evaluated as Valid (series is complete via AstraZeneca 2-dose series)
- Example Scenario #1 - Patient receives the following shots (listed in order): CVX 213, CVX 210 (AstraZeneca), CVX 210 (AstraZeneca)
- evaluate CVX 213 shots given after series completion as Accepted/ EXTRA_DOSE.
- Example Scenario #1 - Patient receives the following shots (listed in order): CVX 210 (AstraZeneca), CVX 210 (AstraZeneca), CVX 213
- Both CVX 210 shots are evaluated as Valid (series is complete via AstraZeneca 2-dose series)
- CVX 213 is evaluated as Accepted/ EXTRA_DOSE
- Example Scenario #1 - Patient receives the following shots (listed in order): CVX 210 (AstraZeneca), CVX 210 (AstraZeneca), CVX 213
- evaluate CVX 213 shots given before series completion as Accepted/ VACCINE_NOT_COUNTED_BASED_ON_MOST_RECENT_VACCINE_GIVEN.
- Target Dose 1, evaluate the shot as Valid.
Rules for COVID-19 Vaccines Not Authorized by FDA2
The following set of rules apply to 1) COVID-19 Vaccines Not Authorized by FDA, but Authorized by WHO and, 2) COVID-19 Vaccines Not Authorized by FDA or WHO, but is an Active COVID-19 Vaccine Candidate as part of a U.S.-based Clinical Trial of a COVID-19 Vaccine.
The list of COVID-19 Vaccines Not Authorized by the FDA, but Authorized by the WHO are:
CVX 210 - AstraZeneca COVID-19 Vaccine
- CVX 510 - BIBP, Sinopharm COVID-19 Vaccine
- CVX 511 - CoronaVac, Sinovac
- CVX 502 - COVAXIN
The list of COVID-19 Vaccines Not Authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine are:
CVX 211- Novavax COVID-19 Vaccine
- If the patient has received all recommended doses of the COVID-19 vaccine, then:
- Evaluate the shots as Valid; (Absolute Minimum Interval = 0 days; Absolute Minimum Age = 0 days)
- No additional doses of COVID-19 vaccine are needed; Recommendation: Not Recommended/ COMPLETE_HIGH_RISK.
- If the patient has received one or more doses, but has not received all the recommended doses for that COVID-19 vaccine, then:
- Evaluate the shot(s) as Accepted/ VACCINE_NOT_APPROVED_IN_US.
- Recommendation:
- If one of the above listed COVID-19 vaccine is the last COVID-19 shot administered, then recommend COVID-19 at the vaccine group level at last shot administered + recommended interval (28 days) or at 5 years old, whichever date is later.
- Example #1: Patient has 1 shot of CVX 210 (AstraZeneca) on record.
- Evaluate CVX 210 as Accepted/ VACCINE_NOT_APPROVED_IN_US.
- Recommend COVID-19 at the vaccine group level for Target Dose 1 at CVX 210 + recommended interval (28 days).
- Example #2: Patient has 1 shot of CVX 208 (Pfizer), then 1 shot of CVX 210 (AstraZeneca) on record.
- Evaluate CVX 208 as Valid and CVX 210 as Accepted/ VACCINE_NOT_APPROVED_IN_US.
- Recommend COVID-19 at the vaccine group level for Target Dose 2 at CVX 210 + recommended interval (28 days).
- If one of the above listed COVID-19 vaccine is NOT the last COVID-19 shot administered, recommend based on the series that applies for the last COVID-19 shot administered.
- Example: If CVX 208 (Pfizer) is given after CVX 210 (AstraZeneca), then recommend based on the Pfizer COVID-19 2-dose Series.
- Example #1: Patient has 1 shot of CVX 210 (AstraZeneca) on record.
- If one of the above listed COVID-19 vaccine is the last COVID-19 shot administered, then recommend COVID-19 at the vaccine group level at last shot administered + recommended interval (28 days) or at 5 years old, whichever date is later.
...
The list of COVID-19 Vaccines Not Authorized by the FDA or WHO are:
- CVX 500 - COVID-19 Non-US Vaccine, Product Unknown
- CVX 501 - COVID-19 IV Non-US Vaccine (QAZCOVID-IN)
- CVX 503 - COVID-19 LAV Non-US Vaccine (COVIVAC)
- CVX 504 - COVID-19 VVnr Non-US Vaccine (Sputnik Light)
- CVX 505 - COVID-19 VVnr Non-US Vaccine (Sputnik V)
- CVX 506 - COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology)
- CVX 507 - COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbology Chinese academy of Sciences)
- CVX 508 - COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention)
- CVX 509 - COVID-19 PS Non-US Vaccine (EpiVacCorona)
- If the patient has received a COVID-19 vaccine not authorized by the FDA or WHO for all or some or the recommended doses of the COVID-19 vaccine, then:
- Evaluate the shot(s) as Invalid/ VACCINE_NOT_APPROVED_IN_US_OR_BY_WHO.
- Recommendation:
- If one of the above listed COVID-19 vaccine is the last COVID-19 shot administered, then recommend COVID-19 at the vaccine group level at last shot administered + recommended interval (28 days) or at 5 years old, whichever date is later.
- Example #1: Patient has 1 shot of CVX 501 on record.
- Evaluate CVX 501 as Invalid/ VACCINE_NOT_APPROVED_IN_US_OR_BY_WHO.
- Recommend COVID-19 at the vaccine group level for Target Dose 1 at CVX 501 + recommended interval (28 days).
- Example #2: Patient has 1 shot of CVX 208 (Pfizer), then 1 shot of CVX 501 on record.
- Evaluate CVX 208 as Valid and CVX 501 as Invalid/ VACCINE_NOT_APPROVED_IN_US_OR_BY_WHO.
- Recommend COVID-19 at the vaccine group level for Target Dose 2 at CVX 501 + recommended interval (28 days).
- Example #1: Patient has 1 shot of CVX 501 on record.
- If one of the above listed COVID-19 vaccine is NOT the last COVID-19 shot administered, recommend based on the series that applies for the last COVID-19 shot administered.
- Example: If CVX 208 (Pfizer) is given after CVX 501, then recommend based on the Pfizer COVID-19 2-dose Series.
- If one of the above listed COVID-19 vaccine is the last COVID-19 shot administered, then recommend COVID-19 at the vaccine group level at last shot administered + recommended interval (28 days) or at 5 years old, whichever date is later.
Rules for an Additional Dose1
Rules for Booster Dose2Any of the FDA-Approved COVID-19 vaccines (except CVX 218) can be used for booster vaccination, regardless of the vaccine product used for primary vaccination. When a heterologous or “mix and match” booster dose is administered, the eligible population and dosing intervals are those of the vaccine used for primary vaccination. Recommendation Rules for Booster Dose or Requirement for a Dose with a Bivalent Vaccine
Evaluation Rules for Booster Dose
Rules for Evaluation of Extra Shots After Additional Dose1 and/or Booster Doses and/or Needed Bivalent Dose2
|
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Notes
|
COVID-19 Vaccines
CVX Code | Name | Absolute Minimum Age | Absolute Maximum Age | Counts towards U.S. Vaccination |
---|---|---|---|---|
207 | Moderna COVID-19 Vaccine | 0 days | Yes | |
208 | Pfizer COVID-19 Vaccine | 0 days | Yes | |
210 | AstraZeneca COVID-19 Vaccine | 0 days | Yes | |
211 | Novavax COVID-19 Vaccine | 0 days | Yes | |
212 | Janssen COVID-19 Vaccine | 0 days | Yes | |
213 | SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED | 0 days | Yes | |
217 | Pfizer COVID-19 Vaccine (>= 12 years) | 0 days | Yes | |
218 | Pfizer COVID-19 Vaccine | 0 days | 18 years - 1 day | Yes |
219 | Pfizer COVID-19 Vaccine | 0 days | 6 years - 1 day | Yes |
221 | Moderna COVID-19 Vaccine | 0 days | Yes | |
227 | Moderna COVID-19 Vaccine (Inactive) | 0 days | 13 years - 1 day | Yes |
228 | Moderna COVID-19 Vaccine | 0 days | 7 years - 1 day | Yes |
229 | Moderna COVID-19 Vaccine, Bivalent | 0 days | Yes | |
230 | Moderna, COVID-19 Vaccine, Bivalent Booster | 0 days | 7 years - 1 day | Yes |
300 | Pfizer COVID-19 Vaccine, Bivalent | 0 days | Yes | |
301 | Pfizer COVID-19 Vaccine, Bivalent | 0 days | 12 years - 1 day | Yes |
302 | Pfizer, COVID-19 Vaccine, Bivalent | 0 days | 6 years - 1 day | |
500 | COVID-19 Non-US Vaccine, Product Unknown | No | ||
501 | COVID-19 IV Non-US Vaccine (QAZCOVID-IN) | No | ||
502 | COVID-19 IV Non-US Vaccine (COVAXIN) | 0 days | Yes | |
503 | COVID-19 LAV Non-US Vaccine (COVIVAC) | No | ||
504 | COVID-19 VVnr Non-US Vaccine (Sputnik Light) | No | ||
505 | COVID-19 VVnr Non-US Vaccine (Sputnik V) | No | ||
506 | COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology) | No | ||
507 | COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbology Chinese academy of Sciences) | No | ||
508 | COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) | No | ||
509 | COVID-19 PS Non-US Vaccine (EpiVacCorona) | No | ||
510 | COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) | 0 days | Yes | |
511 | COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) | 0 days | Yes | |
512 | COVID-19 VLP Non-US Vaccine (Medicago, Covifenz) | 18 years - 4 days | Yes | |
513 | COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax) | No | ||
514 | COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D) | No | ||
515 | COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901) | No | ||
516 | COVID-19 Inactivated Non-US Vaccine (Minhai Biotechnology Co, KCONVAC) | No | ||
517 | COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax) | No | ||
518 | COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva) | No | ||
519 | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna | 0 days | Yes | |
520 | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech | 0 days | Yes | |
521 | COVID-19 SP, protein-based, adjuvanted (VidPrevtyn Beta), Sanofi-GSK | No |
Combination Vaccines that Include COVID-19
No combination vaccines exist, at this time, that include COVID-19 and count toward completion of the Pfizer COVID-19 2-dose series.
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
CVX Code Specific RulesCVX Code Absolute Minimum Age
CVX Code Absolute Maximum Age
Rule for CVX 218, CVX 219, CVX 227, CVX 228, CVX 229, CVX 230, CVX 301, CVX 302
Rule for Bivalent Vaccines (CVX 229, CVX 230, CVX 300, CVX 301, CVX 301, CVX 519, CVX 520)
Rule for CVX 213
Rules for COVID-19 Vaccines Not Authorized by FDA2The following set of rules apply to 1) COVID-19 Vaccines Not Authorized by FDA, but Authorized by WHO and, 2) COVID-19 Vaccines Not Authorized by FDA or WHO, but is an Active COVID-19 Vaccine Candidate as part of a U.S.-based Clinical Trial of a COVID-19 Vaccine.
|
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Notes
|
Immunization Series and Selection Rules
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Name
Series Selection RulesThere are five series for this vaccine group: Pfizer COVID-19 Series, Moderna COVID-19 Series, Mixed Product COVID-19 Series, Janssen COVID-19 Series, and Novavax COVID-19 Series. The rules for determining which series applies are:
|
Immunization Series: Pfizer COVID-19 Series
The Pfizer COVID-19 Series is complete after 2 or 3 doses, depending on age (not including booster dose(s)).
Vaccine Dose Parameters - Minimum and Routine Ages
Dose | Series Name | Absolute Minimum Age | Minimum Age | Routine Age | Latest Recommended Age (less than) | Valid CVX Code(s) per Dose for this Series | Invalid CVX Code(s) per Dose for this Series |
---|---|---|---|---|---|---|---|
1 | Pfizer COVID-19 Series | 0 days | 6 months | 6 months | N/A | 208, 217, 218, 219, 300, 301, 302 | 229, 230 |
2 | Pfizer COVID-19 Series | 0 days | 6 months | 6 months | N/A | 208, 217, 218, 219, 300, 301, 302 | 229, 230 |
3 | Pfizer COVID-19 Series | 0 days | 6 months | 6 months | N/A | 208, 217, 218, 219, 300, 301, 302 | 229, 230 |
Vaccine Dose Parameters - Minimum and Recommended Intervals
Doses | Series Name | Absolute Minimum Interval | Minimum Interval | Recommended Interval | Latest Recommended Interval (less than) |
---|---|---|---|---|---|
Dose 1 to 2 | Pfizer COVID-19 Series | 8 weeks - 4 days if dose 2 administered >= 4/19/2023 and dose 1 administered >= 5 years of age Otherwise, 17 days | 8 weeks if the execution date is >= 4/19/2023 and dose 1 was administered >= 5 years of age Otherwise, 21 days | 8 weeks if the execution date is >= 4/19/2023 and dose 1 was administered >= 5 years of age Otherwise, 21 days |
N/A |
Dose 2 to 3 | Pfizer COVID-19 Series | 8 weeks - 4 days | 8 weeks | 8 weeks | N/A |
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Special Rules
Vaccine to Recommend
Skip Dose Rule
Rule for CVX 212 (Janssen COVID-19 vaccine)
|
Immunization Series: Moderna COVID-19 Series
The Moderna COVID-19 series is complete after 2 doses(not including booster dose(s)).
Vaccine Dose Parameters - Minimum and Routine Ages
Dose | Series Name | Absolute Minimum | Minimum Age | Routine | Latest Recommended Age (less than) | Valid CVX Code(s) per Dose for this Series | Invalid CVX Code(s) per Dose for this Series |
---|---|---|---|---|---|---|---|
1 | Moderna COVID-19 Series | 0 days | 6 months | 6 months | N/A | 207, 221, 227, 228, 229 | N/A |
2 | Moderna COVID-19 Series | 0 days | 6 months | 6 months | N/A | 207, 221, 227, 228, 229 | N/A |
Vaccine Dose Parameters - Minimum and Recommended Intervals
Doses | Series Name | Absolute Minimum Interval | Minimum Interval | Recommended Interval | Latest Recommended Interval (less than) |
---|---|---|---|---|---|
Dose 1 to 2 | Moderna COVID-19 | 0 days if dose 2 administered < 10/25/2021 8 weeks - 4 days if dose 2 administered >= 4/19/2023 and dose 1 administered >= 6 years of age Otherwise, 24 days if dose 2 administered >= 10/25/2021 | 8 weeks if the execution date is >= 4/19/2023 and dose 1 was administered >= 6 years of age Otherwise, 28 days | 8 weeks if the execution date is >= 4/19/2023 and dose 1 administered >= 6 years of age Otherwise, 28 days | N/A |
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Special Rules
Vaccine to Recommend
Rule for CVX 212 (Janssen COVID-19 vaccine)
|
Immunization Series: Mixed Product COVID-19 Series
The Mixed Product COVID-19 Series is complete after 2 or 3 doses, depending on age(not including booster dose(s)).
Vaccine Dose Parameters - Minimum and Routine Ages
Dose | Series Name | Absolute Minimum | Minimum Age | Routine | Latest Recommended Age (less than) | Valid CVX Code(s) per Dose for this Series | Invalid CVX Code(s) per Dose for this Series |
---|---|---|---|---|---|---|---|
1 | Mixed Product COVID-19 Series | 0 days | 6 months | 6 months | N/A | 207, 208, 211, 213, 217, 218, 219, 221, 227, 228, 300, 301, 302 | 229, 230 |
2 | Mixed Product COVID-19 Series | 0 days | 6 months | 6 months | N/A | 207, 208, 211, 213, 217, 218, 219, 221, 227, 228, 300, 301, 302 | 229, 230 |
3 | Mixed Product COVID-19 Series | 0 days | 6 months | 6 months | N/A | 207, 208, 211, 213, 217, 218, 219, 221, 227, 228, 300, 301, 302 | 229, 230 |
Vaccine Dose Parameters - Minimum and Recommended Intervals
Doses | Series Name | Absolute Minimum Interval | Minimum Interval | Recommended Interval | Latest Recommended Interval (less than) |
---|---|---|---|---|---|
Dose 1 to 2 | Mixed Product COVID-19 Series | 8 weeks - 4 days if dose 2 administered >= 4/19/2023 and dose 1 administered >= 5 years of age Otherwise:
| 8 weeks if the execution date is >= 4/19/2023 and dose 1 was administered >= 5 years of age Otherwise, 28 days | 8 weeks if the execution date is >= 4/19/2023 and dose 1 was administered >= 5 years of age Otherwise, 28 days | N/A |
Dose 2 to 3 | Mixed Product COVID-19 Series | 8 weeks - 4 days | 8 weeks | 8 weeks | N/A |
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Special Rules
Vaccine to Recommend
Skip Dose Rule
Rule for CVX 211 (Novavax COVID-19 vaccine)
Rule for CVX 212 (Janssen COVID-19 vaccine)
|
Immunization Series: Janssen COVID-19 Series
The Janssen COVID-19 Series is complete after 1 dose.
Vaccine Dose Parameters - Minimum and Routine Ages
Dose | Series Name | Absolute Minimum | Minimum Age | Routine | Latest Recommended Age (less than) | Valid CVX Code(s) per Dose for this Series | Invalid CVX Code(s) per Dose for this Series |
---|---|---|---|---|---|---|---|
1 | Janssen COVID-19 Series | 0 days | 18 years | 18 years | N/A | 212 | N/A |
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Special Rules
|
Immunization Series: Novavax COVID-19 Series
The Novavax COVID-19 Series is complete after 2 doses (not including booster dose(s)).
Vaccine Dose Parameters - Minimum and Routine Ages
Dose | Series Name | Absolute Minimum | Minimum Age | Routine | Latest Recommended Age (less than) | Valid CVX Code(s) per Dose for this Series | Invalid CVX Code(s) per Dose for this Series |
---|---|---|---|---|---|---|---|
1 |
Novavax COVID-19 |
Series |
12 years - 4 days |
12 years |
12 years | N/A |
211 | |||||
2 | Novavax COVID-19 Series | 12 years - 4 days | 12 years | 12 years | N/A |
...
borderColor | #CCFFFF |
---|---|
bgColor | #CCFFFF |
titleBGColor | #99FFFF |
borderStyle | solid |
Series Special Rules
...
211 |
Vaccine Dose Parameters - Minimum and Recommended Intervals
Doses | Series Name | Absolute Minimum Interval | Minimum Interval | Recommended Interval | Latest Recommended Interval (less than) |
---|---|---|---|---|---|
Dose 1 to 2 | Novavax COVID-19 Series | 17 days | 21 days | 21 days | 8 weeks |